Improved Self-management for Patients on Ventricular Assist Device (VAD)

NCT ID: NCT04234230

Last Updated: 2020-11-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

393 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-01

Study Completion Date

2020-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The number of patients with end-stage heart disease requiring the implantation of ventricular assist devices (VAD) is steadily increasing. Living with a VAD exposes the patients to multiple challenges and the need to learn complex self-management skills. Inadequate self-management can lead to serious complications (e.g. bleeding or wound infections) and impair the psychosocial outcome. This study aims to provide multi-centered actual analysis of self-management capabilities as well as analyzing moderating predictors in VAD patients through standardized prevalence assessment. Using a cross-sectional design, this prevalence study will be conducted at four established German heartcenters (Freiburg, Berlin, Bad Oeynhausen, Leipzig). VAD-patients are questioned about their self-management skills using standardized Patient-reported outcome (PRO) measures. Secondary PRO measures include health-related quality of life, symptoms of anxiety and depression, post-traumatic stress symptoms, social support, and changed body-image. Relevant complications (bleeding, wound infections, thromboembolic neurological events) are taken from the patient records. Based on a conservative sample size estimation inclusion of 450 patients is envisioned. The expected results may contribute to an improved assessment of the current situation in terms of self-management skills and needs for curricular training concepts and psychosocial concomitant therapy. Long-term, the study results contribute to improve the health care for long-term VAD patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The number of patients with end-stage heart disease requiring the implantation of ventricular assist devices (VAD) is steadily increasing. Due to advanced compensatory technological developments, VAD support has been established as a recognized therapy concept for the long-term care of those affected. Indications include a multi-year bridging therapy (up to 10 years) and increasingly a destination therapy. The Euromacs Register published the second report in 2018 and reported 2,947 registered VAD implantations in 2016 (+257 percent). Euromacs further points to a rising trend and demand for the use of VAD systems. In Germany, an increase of VAD implantation by 36.6 percent has been reported since 2011. The position paper of the German Society of Cardiology (2016) points to the fact that the range of indications for VAD implantation for patients with chronic heart disease will continue to change. The ISHLT Guideline (International Society for Heart and Lung Transplantation), published in 2018, calls for psychosocial care and standardized self-management skills for patients before, during, and in the long-term after VAD implantation. This is currently being implemented inconsistently in terms of structure and quality in German cardiac centers. After VAD implantation, patients and their relatives must be able to follow a complex therapeutic regimen. They need comprehensive knowledge as well as self-management skills for the safe management of everyday life in a domestic setting. These self-management capabilities include the so-called device handling (for example dealing with the technical equipment including battery replacement and controller monitoring), to perform the wound care of the driveline, to carry out anticoagulation measurements and adapted revenues of oral anticoagulant, to take further medication, to monitor vital signs (for example blood pressure, temperature) and, in the case of symptoms, to take adequate measures to prevent further complications (for example prompt information from the heart center on the onset of symptoms). In addition, lifestyle changes are an essential part of the success of long-term therapy. This requires a sufficient degree of self-management ability and mental stability. In addition, it is important to emotionally accept the dependence of a device on the heart, the changed body image, to cope with fears of (real potential) malfunctions and complications and to build up a subjective quality of life with a constant, visible and tangible companion at heart. The mental health of all those affected is considered to be in need of observation, although there is currently no reliable prevalence data on mental disorders. In a first survey in 2006, 64% had at least one psychologically / psychiatric treatment requiring diagnosis. All this shows, the challenges VAD patients have to face are complex. Thus, this study aims to provide multi-centered actual analysis of self-management capabilities as well as analyzing moderating predictors in VAD patients through standardized PRO prevalence assessment. The prevalence survey should be conducted in all outpatients (at least 3 months up to a maximum of 3 years at the VAD) in four established German cardiac centers (Freiburg, Berlin, Bad Oeynhausen, Leipzig). The study focuses on those involved in outpatient care, as they had to integrate the VAD into their daily lives after implantation and are able to report deficits, resources and needs on the basis of their experience of self-management. As an assessment instrument a standardized PRO measure was chosen to identify self-management skills and needs. Secondary PRO measures include health-related quality of life, symptoms of anxiety, depression and post-traumatic stress, as well as social support. Relevant complications (bleeding, wound infections, thromboembolic neurological events) are taken from the patient records. Based on a conservative sample size estimation inclusion of 450 patients is envisioned. The expected results may contribute to an improved assessment of the current situation in terms of self-management skills and needs for curricular training concepts and psychosocial concomitant therapy. Long-term, the study results contribute to improve the health care for long-term VAD patients. The study is planned to continue in a second and third phase to develop and test a standardized self-management care for VAD patients in Germany.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ventricular Assist Device Self-management Psychological Factors

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Ventricular Assist Device Self-management Psychosocial Factors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VAD Patients

Patients with implanted ventricular assist device in the outpatient setting

Prevalence Survey

Intervention Type OTHER

Questionnaire survey on self-management

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prevalence Survey

Questionnaire survey on self-management

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Outpatient at the respective heart center
* Living in a home environment
* On device between 3 months and 3 years
* 18 years and older
* No contraindications (e.g. cognitive, language)
* Signed Informed Consent

Exclusion Criteria

* In-patient stay
* Not living in a home environment (e.g. assisted living)
* On device less than 3 months or more than 3 years
* Underage
* Contraindications (e.g. cognitive, language)
* No signed Informed Consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Heart Center Freiburg - Bad Krozingen

OTHER

Sponsor Role collaborator

Heart and Diabetes Center North-Rhine Westfalia

OTHER

Sponsor Role collaborator

German Heart Center

OTHER

Sponsor Role collaborator

Heart Center Leipzig - University Hospital

OTHER

Sponsor Role collaborator

University of Freiburg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Christiane Kugler

Professor Doctor. rer. biol. hum.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christiane Kugler, Prof. Dr.

Role: STUDY_DIRECTOR

University of Freiburg

Christiane Kugler, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

University of Freiburg

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Heart Center Freiburg

Freiburg im Breisgau, Baden-Wurttemberg, Germany

Site Status

Heart and Diabetes Center North Rhine-Westphalia

Bad Oeynhausen, North Rhine-Westphalia, Germany

Site Status

Leipzig Heart Center

Leipzig, Saxony, Germany

Site Status

German Heart Center

Berlin, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Kugler C, Spielmann H, Albert W, Lauenroth V, Spitz-Koeberich C, Semmig-Koenze S, Staus P, Tigges-Limmer K; SELMA Study Group. Professional Employment in Patients on Ventricular Assist Device Support-A National Multicenter Survey Study. ASAIO J. 2024 May 1;70(5):348-355. doi: 10.1097/MAT.0000000000002124. Epub 2024 Jan 3.

Reference Type DERIVED
PMID: 38170263 (View on PubMed)

Spielmann H, Tigges-Limmer K, Albert W, Spitz-Koberich C, Semmig-Konze S, Staus P, Herrmann-Lingen C, Sandau KE, Okeson B, Geyer S, Kugler C; Selma Study Group. Health-Related Quality of Life in Patients With Ventricular Assist Device: Psychometric Evaluation of the German Version of the Quality of Life With a Ventricular Assist Device Questionnaire. J Cardiovasc Nurs. 2024 Nov-Dec 01;39(6):571-582. doi: 10.1097/JCN.0000000000001064. Epub 2023 Nov 22.

Reference Type DERIVED
PMID: 37991265 (View on PubMed)

Spielmann H, Albert W, Semmig-Konze S, Lauenroth V, Spitz-Koberich C, Staus P, Tigges-Limmer K, Kugler C; SELMA Study Group. High level of psychosocial adjustment in patients on ongoing ventricular assist device support in the years one to three after VAD implantation-A national multi-center Study. Heart Lung. 2024 Jan-Feb;63:92-97. doi: 10.1016/j.hrtlng.2023.10.003. Epub 2023 Oct 12.

Reference Type DERIVED
PMID: 37837720 (View on PubMed)

Kugler C, Spielmann H, Seemann M, Lauenroth V, Wacker R, Albert W, Spitz-Koeberich C, Semmig-Koenze S, von Cube M, Tigges-Limmer K. Self-management for patients on ventricular assist device support: a national, multicentre study: protocol for a 3-phase study. BMJ Open. 2021 May 5;11(5):e044374. doi: 10.1136/bmjopen-2020-044374.

Reference Type DERIVED
PMID: 33952544 (View on PubMed)

Spielmann H, Seemann M, Friedrich N, Tigges-Limmer K, Albert W, Semmig-Konze S, Spitz-Koberich C, Kugler C. Self-management with the therapeutic regimen in patients with ventricular assist device (VAD) support - a scoping review. Heart Lung. 2021 May-Jun;50(3):388-396. doi: 10.1016/j.hrtlng.2021.01.019. Epub 2021 Feb 20.

Reference Type DERIVED
PMID: 33621837 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

01VSF18012

Identifier Type: -

Identifier Source: org_study_id